Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DOMH
- Company Dominari Holdings Inc.
- Price $0.82
- Changes Percentage -5.52
- Change -0.0479
- Day Low $0.82
- Day High $0.88
- Year High $7.54
- Year Low $1.91
- Market Cap $52,011,696
- Price Avg 50 EMA (D) $2.5
- Price Avg 200 EMA (D) $3.22
- Exchange NASDAQ
- Volume 615,935
- Average Volume 166,947
- Open $0.83
- Previous Close $0.87
- EPS -11.44
- PE -0.20
- Earnings Announcement 2026-11-05 12:00:00
- Shares Outstanding $22,613,781
Company brief: DOMINARI HOLDINGS INC. (DOMH )
- Healthcare
- Biotechnology
- Mr. Anthony C. Hayes Esq.
- https://www.aikidopharma.com
- US
- N/A
- 03-18-1980
- US0088753043
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
